<\/b><\/p>\n
<\/b><\/p>\n
TUESDAY, March 24, 2020 (HealthDay News) — A once-daily, three-drug combination treatment reduces mortality for patients with symptomatic chronic obstructive pulmonary disease (COPD) who are at risk for future exacerbations, according to a study published online March 12 in the American Journal of Respiratory and Critical Care Medicine<\/i>.<\/p>\n
David A. Lipson, M.D., from GlaxoSmithKline in Collegeville, Pennsylvania, and colleagues reported all-cause mortality (ACM) and the impact of stepping down therapy following collection of additional vital status data from the phase 3 IMPACT trial. Patients had been randomly assigned (2:2:1) to fluticasone furoate\/umeclidinium\/vilanterol (FF\/UMEC\/VI), FF\/VI, or UMEC\/VI following an exacerbation on their COPD therapies.<\/p>\n
The researchers found that among 10,355 participants, there were 98 deaths (2.36 percent) on FF\/UMEC\/VI, 109 deaths (2.64 percent) on FF\/VI, and 66 deaths (3.19 percent) on UMEC\/VI. Corresponding hazard ratios for death were 0.72 for FF\/UMEC\/VI versus UMEC\/VI (95 percent confidence interval, 0.53 to 0.99; P = 0.042) and 0.89 for FF\/UMEC\/VI versus FF\/VI (95 percent confidence interval, 0.67 to 1.16; P = 0.387). Lower rates of cardiovascular and respiratory death as well as death associated with the patient’s COPD were confirmed by independent adjudication.<\/p>\n
“In this secondary analysis of an efficacy outcome from the IMPACT trial, once-daily single-inhaler FF\/UMEC\/VI triple therapy reduced the risk of ACM versus UMEC\/VI in patients with symptomatic COPD and a history of exacerbations,” the authors write.<\/p>\n
Several authors disclosed financial ties to GlaxoSmithKline, which funded the study.<\/p>\n
Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n